The use of a protein tyrosine kinase pathway inhibitor in the treatment of ocular disorders
CA 2373178 C · Owner: Johns Hopkins University School Of Medicine · Inventors: De Juan, Eugene Jr.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The present invention is directed to a method for the prophylactic and therapeutic treatment of age-related macular degeneration as well as methods for the prophylactic and therapeutic treatment of exudative and atrophic complications of age-related macular degeneration. The methods involve the administration of an inhibitor of the protein tyrosine kinase pathway to an animal, such as a mammal, in particular a human in an amount sufficient to , treat the animal for age-related macular degeneration or an exudative or atrophic complication thereof, respectively prophylactically or , therapeutically. The present invention further provides a method for the prophylactic and therapeutic …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed May 5, 2000 and granted July 2, 2013. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended May 5, 2020.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by May 5, 2022.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.